



LABAT AFRICA LIMITED

(Incorporated in the Republic of South Africa)
(Registration number 1986/001616/06)
("Labat Africa" or "the Company")
ISIN Code: ZAE000018354 Share code: LAB

VOLUNTARY ANNOUNCEMENT RELATING TO THE APPROVAL OF OBSERVATIONAL RESEARCH TRIALS TO INVESTIGATE THE REPLACEMENTS OF OPIOIDS WITH MEDICAL CANNABIS FOR PAIN MANAGEMENT WITHIN THE SOUTH AFRICAN POPULATION BY THE PHARMA-ETHICS COMMITTEE

FIRST SOUTH AFRICAN COMPANY TO RECEIVE PHARMA-ETHICS COMMITTEE APPROVAL FOR CANNABIS RESEARCH

Shareholders are advised that Labat Africa's subsidiary, Biodata (Pty) Limited ("Biodata"), headed by Dr Shiksha Gallow as the Principal Investigator of the study, has received the Ethics Committee approval to conduct an observational research trial to replace Opioids with Medical Cannabis for Pain Management. The sponsor of the study is Labat Healthcare and is one of the first Medical cannabis research observational trials in South Africa.

Biodata is focused on the Cannabis industry and was initially set up as a Holistic Healing Enterprise incorporating Cannabinoid healing. The Company is currently well positioned to commence with formalised Clinical Trials focused on Pain Management and Insomnia.

The research conducted by Dr Gallow on Cannabinoids, Ayurvedic medicine as well as Homeopathic medicines is a significant enhancement to Labat Africa's Nutraceutical and Pharmaceutical offerings. With the growing international trend of opiate addiction and its impact on overdoses, ill-health and crime, with countries worldwide searching desperately for safer alternatives to treat severe and mild pain. The Research study has been accepted as complying to the Ethics Standards for Clinical Research with a new drug based on FDA, ICH, GCP and the declaration of Helsinki guidelines.

The study investigates the replacement of opioids with medical cannabis, and would help practitioners understand the effects of cannabinoids for pain management and stress related disorders. Dr Gallow has received Pharma Ethics approval for this study, making it the first cannabis study receiving ethics approval in SA. This is a large-scale study using Medical Cannabis Real World Evidence (MC-RWE), as 1 000 participants will be recruited using three different sites. Patients pain management while on medical cannabis will be observed and documented, side effects will also be noted as well as drug interactions. The study includes the use of both the cannabis flower and cannabis oil, patients will be recruited once they are eligible for the study according to the inclusion and exclusion criteria set out by Dr Gallows protocol. There are innumerable benefits that will result from this research and practitioners and researchers alike, are anxiously waiting for this study to go live. Now that the trials have been approved, Dr Gallow and her team of doctors will begin the recruitment of patients. Dr Gallows' team includes likeminded practitioners, who understand the benefits of cannabis for medicinal purposes. Her team includes: Dr Regina Hurley, Dr Ahmed Jamalooden, Dr Xavagne Fransman and Dr Omphemetse Mathibe. Other collaborators include Dr Marian Tupy.

The Ethics Committee further commented: "THE ETHICS COMMITTEE (IRB) grants this approval in compliance with the guidelines for Good Practice in the Conduct of Clinicals Trials in Human Participants in South Africa (200), ICH Harmonised Tripartite Guidelines EC; Note for the guidance in Good Clinical practice (CPMP/ICH/135/95) and FDA code of Federal Regulation, Part 50, 56 and 312."

In correspondence sent to Biodata by The Ethics Committee on 9 June 2021, they informed Biodata that all conditions were met to the satisfaction of the Committee and thus this constitutes the final Ethics Approval.

The approval is as a result of many hours of hard work by the research team for which they must be congratulated and it certainly places Labat Africa a few years ahead with respect to Medical Cannabis and opens the door for Labat Africa's growing and cultivation operation in Upington to accelerate the development of its medical strains.

Johannesburg

18 June 2021

Sponsor

AcaciaCap Advisors Proprietary Limited

